Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at QuidelOrtho (NASDAQ: QDEL) and the best and worst performers in the healthcare equipment and supplies industry.
The healthcare equipment and supplies sector thrives on innovation in medical devices and consumables, the latter providing recurring revenue. Future growth is buoyed by an aging population with increasing chronic diseases and a shift towards minimally-invasive surgery. Advancements in materials science and AI-driven diagnostics also offer significant opportunities. Key headwinds remain, including pricing pressure from cost-conscious healthcare providers, evolving regulations, and potential supply chain disruptions.
The 37 healthcare equipment and supplies stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 2.3% while next quarter’s revenue guidance was 1.3% below.
Thankfully, share prices of the companies have been resilient as they are up 6.6% on average since the latest earnings results.
QuidelOrtho (NASDAQ: QDEL)
Born from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (NASDAQ: QDEL) develops and manufactures diagnostic testing solutions for healthcare providers, from rapid point-of-care tests to complex laboratory instruments and systems.
QuidelOrtho reported revenues of $619.8 million, down 10.5% year on year. This print fell short of analysts’ expectations by 7.3%. Overall, it was a softer quarter for the company with a significant miss of analysts’ full-year EPS guidance estimates.
"Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho.
QuidelOrtho delivered the weakest performance against analyst estimates of the whole group. Interestingly, the stock is up 45.7% since reporting and currently trades at $16.99.
Read our full report on QuidelOrtho here, it’s free.
Best Q1: STAAR Surgical (NASDAQ: STAA)
With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ: STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens.
STAAR Surgical reported revenues of $93.52 million, up 120% year on year, outperforming analysts’ expectations by 20.8%. The business had an incredible quarter with a beat of analysts’ EPS estimates.
STAAR Surgical delivered the biggest analyst estimate beat and fastest revenue growth among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 9.7% since reporting. It currently trades at $26.54.
Is now the time to buy STAAR Surgical? Access our full analysis of the earnings results here, it’s free.
Weakest Q1: Stryker (NYSE: SYK)
With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.
Stryker reported revenues of $6.02 billion, up 2.6% year on year, falling short of analysts’ expectations by 5%. It was a disappointing quarter as it posted a significant miss of analysts’ EPS and organic revenue estimates.
Interestingly, the stock is up 4.1% since the results and currently trades at $328.20.
Read our full analysis of Stryker’s results here.
ResMed (NYSE: RMD)
Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE: RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.
ResMed reported revenues of $1.43 billion, up 10.8% year on year. This print surpassed analysts’ expectations by 0.8%. It was a satisfactory quarter as it also put up a beat of analysts’ EPS estimates.
The stock is up 2.1% since reporting and currently trades at $218.26.
Read our full, actionable report on ResMed here, it’s free.
Integer Holdings (NYSE: ITGR)
With its name reflecting the mathematical term for "whole" or "complete," Integer Holdings (NYSE: ITGR) is a medical device outsource manufacturer that produces components and systems for cardiac, vascular, neurological, and other medical applications.
Integer Holdings reported revenues of $439.6 million, flat year on year. This result beat analysts’ expectations by 3.1%. Taking a step back, it was a slower quarter as it recorded a significant miss of analysts’ full-year EPS and revenue estimates.
The stock is up 9.8% since reporting and currently trades at $91.84.
Read our full, actionable report on Integer Holdings here, it’s free.
Market Update
Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?
These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.
Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
